Autologous Anti-CD19/CD20/CD22 CAR T-cells Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Autologous Anti-CD19/CD20/CD22 CAR T Cells, Autologous Anti-CD19/CD20/CD22 CAR-T Cells, Autologous CAR19.20.22 CAR T-cells

Filter by location:

Columbus, Ohio1 trial

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.